Pharma & Biotech Mergers & Acquisitions News
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss drug major Novartis says it is divesting its blood transfusion diagnostics unit to Spain’s Grifols for $1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014. 11 November 2013
Pharmaceutical
Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning, after it said it has agreed terms to acquire US orphan drug company ViroPharma for $50 a share in cash. 11 November 2013
Pharmaceutical
The US Federal Trade Commission yesterday (November 6) issued final changes to the premerger notification rules that require companies in the pharmaceutical industry to report certain proposed acquisitions of exclusive patent rights to the FTC and the Department of Justice for antitrust review. 7 November 2013
Pharmaceutical
Sorrento Therapeutics has acquired Sherrington Pharmaceuticals. Financial terms of the deal were not disclosed. 16 October 2013
Pharmaceutical
Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D collaboration focused on discovering and developing novel drugs that improve mitochondrial functions. 7 October 2013
Pharmaceutical
GlaxoSmithKline says it has now reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the Notre-Dame de Bondeville, France, manufacturing site to Aspen Pharmacare for £700 million. 30 September 2013
Pharmaceutical
In a second takeover deal this year, Italian drugmaker Recordati (RC: MI) says it has signed agreements to acquire 100% of the share capital of Laboratorios Casen Fleet, a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza. 9 September 2013
Pharmaceutical
California, USA-based XOMA Corp (Nasdaq: XOMA) says it has transferred US development and commercialization rights to the perindopril franchise to start up Symplmed Pharmaceuticals. XOMA acquired the US perindopril franchise rights from independent French drugmaker Servier last year (The Pharma Letter January 18). 8 July 2013
Pharmaceutical
Family-owned German drug major Boehringer Ingelheim has submitted an application to the European Medicines Agency) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE. Rival drug Xarelto (rivaroxaban), from Germany's Bayer, gained European approval for DVT and PE last year (The Pharma Letter November 21, 2012). 25 June 2013
Pharmaceutical
In the ongoing hostile takeover saga, US private equity firm Royalty Pharma has withdrawn its request for a judicial review of the Irish Takeover Panel's decision requiring it to lapse its offer for drugmaker Elan Corp (NYSE: ELN) oration, if, among other things, Elan shareholders approved the Share Repurchase Program (The Pharma Letter June 18). 19 June 2013
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday (June 18) that it has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global and Aspen Pharmacare (JSE: APN), South Africa's largest drugmaker. A period of exclusivity has been agreed with Aspen and GSK will respond to the offer subject to consultation with employees and the relevant works councils. 19 June 2013
Pharmaceutical
Ireland-based drugmaker Elan Corp (NYSE: ELN) says that its board of directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has rejected the revised bid from privately held investment firm Royalty Pharma to acquire all of the shares of Elan for $13.00 plus up to an additional $2.50 per share in contingent value rights (CVR; The Pharma Letter June 10). 11 June 2013
Pharmaceutical
Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy area, with the planned acquisition of UK-based Profile Pharma from present owner the Philips Group. Financial details of this transaction will not be disclosed. 10 June 2013
Pharmaceutical
In what seems to be confirmation that adjuvants are fast becoming a serious element in vaccine development, USA-based Novavax (Nasdaq: NVAX) revealed that it has made a public tender offer to acquire Sweden-based Isconova (OMX: ISCO) directly from shareholders and intends to make a private offer for all outstanding stock options. 7 June 2013
Pharmaceutical
West Chester-based, USA, Aqua Pharmaceuticals says it has acquired the US rights to, and re-launch of, Verdeso (desonide) Foam, 0.05% from Stiefel, a subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK). Financial terms of the deal were not disclosed. 5 June 2013
Pharmaceutical
US specialty drugmaker Depomed (Nasdaq: DEPO) says that Food and Drug Administration issued a complete response letter (CRL) to the New Drug Application for Sefelsa, the firm's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause. 3 June 2013
Pharmaceutical
Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's (OTC BB: ARDM.OB) proprietary formulations of inhaled ciprofloxacin (brand names Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase IIb clinical trials in BE patients with Pulmaquin and Lipoquin. 23 May 2013
Pharmaceutical
Russian drugmaker Pharmstandard is to acquire Petrovax Pharm, one of the country's largest producers of vaccines. The deal has already been approved by the Russian Federal Anti-Monopoly Service (FAS), which just a couple of week ago imposed a ban on the acquisition of Petrovax by the USA's Abbott Laboratories (NYSE: ABT), due to reasons of national security. 7 May 2013
Pharmaceutical
German drugs and chemical major Bayer (BAYN: DE) has signed an agreement to acquire Conceptus (Nasdaq: CPTS), the California, USA, based developer of the Essure procedure, the leading non-surgical permanent birth control method, which is sold in the USA and other countries. 29 April 2013
Pharmaceutical
Florida biopharma Ligand Pharmaceuticals subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics, a developer of non-opioid pain treatments. 17 April 2025
Pharmaceutical
Dutch specialty pharma firm Norgine Pharmaceuticals has entered into a definitive agreement to acquire Theravia, a French pharmaceutical company specializing in cutting-edge treatments for patients with rare and debilitating conditions from Mérieux Equity Partners. 16 April 2025
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
Pharmaceutical
Florida-based MIRA Pharmaceuticals, a pharma company developing therapeutics for neurologic and neuropsychiatric disorders, has signed a binding letter of intent (LOI) to acquire privately held Delaware firm SKNY Pharmaceuticals. 24 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
Pharmaceutical
Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based pharmaceutical company at approximately £362 million ($468 million). 11 March 2025
Pharmaceutical
USA-based Endo Inc today announced it has entered into a definitive agreement to divest its international pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma to Knight Therapeutics. 11 March 2025
Pharmaceutical
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and AstraZeneca. US pharma major AbbVie became the latest entrant to the weight management sector, striking a deal with Gubra for its obesity candidate GUB14295. On the M&A front, Ireland-headquartered Jazz Pharmaceuticals announced it is acquiring Chimerix for around $935 million to expand its oncology portfolio. USA-based scPharmaceuticals gained US Food and Administration (FDA) approval for its supplemental new drug application (sNDA) for Furoscix in chronic kidney disease (CKD). 9 March 2025
Pharmaceutical
Private equity firms acquiring assets were among the most eye-catching deals in pharma M&A during February. 6 March 2025
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix for $8.55 per share in cash, representing a total consideration of around $935 million. The news sent Chimerix’ shares rocketing almost 70% to $8.40. 5 March 2025
Pharmaceutical
French biotech start-up studio Argobio and non-profit biomedical research center the Institut Pasteur have announced the launch of Enodia Therapeutics. 26 February 2025
Pharmaceutical
Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK pharma business, Alturix Holdings Limited. Financial terms were not disclosed. 24 February 2025
Pharmaceutical
US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Australia-based Mayne Pharma with the aim of expanding its health portfolio. 21 February 2025
Pharmaceutical
FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the news sending the California-based company’s shares soaring 27% to $0.71. 20 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze